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ABSTRACT: Enhanced passive diffusion is usually considered to be the
primary cause of the enhanced cellular uptake of cyclometalated drugs
because cyclometalation lowers the charge of a metal complex and
increases its lipophilicity. However, in this work, monocationic
cyclometalated palladium complexes [1]OAc (N^N^C^N) and
[2]OAc (N^N^N^C) were found to self-assemble, in aqueous solutions,
into soluble supramolecular nanorods, while their tetrapyridyl bicationic
analogue [3](OAc)2 (N^N^N^N) dissolved as isolated molecules.
These nanorods formed via metallophilic Pd···Pd interaction and π−π
stacking and were stabilized in the cell medium by serum proteins, in the
absence of which the nanorods precipitated. In cell cultures, these
protein-stabilized self-assembled nanorods were responsible for the
improved cellular uptake of the cyclometalated compounds, which took
place via endocytosis (i.e., an active uptake pathway). In addition to
triggering self-assembly, cyclometalation in [1]OAc also led to dramatically enhanced photodynamic properties under blue light
irradiation. These combined penetration and photodynamic properties were observed in multicellular tumor spheroids and in a mice
tumor xenograft, demonstrating that protein-stabilized nanoaggregation of cyclometalated drugs such as [1]OAc also allows efficient
cellular uptake in 3D tumor models. Overall, serum proteins appear to be a major element in drug design because they strongly
influence the size and bioavailability of supramolecular drug aggregates and hence their efficacy in vitro and in vivo.
■ INTRODUCTION
Research on metal-based anticancer drugs has been encour-
aged for many years by the clinical success of cisplatin,
carboplatin, oxaliplatin, and nedaplatin, four metal-based drugs
used in the treatment of cancer.1−3 However, the similar mode
of action of these platinum-based compounds, where aquation
of some of the leaving groups by intracellular water leads to
nonselective covalent binding of platinum to DNA, results in
significant side effects and drug resistance.3−10 Several
strategies have been developed to overcome these drawbacks,
in particular, photodynamic therapy (PDT). PDT is a fast-
developing cancer treatment modality because it shows
reduced systemic cytotoxicity to cancer patients.11−13 In
PDT, a photosensitizing agent (PS) is injected, and upon
light at the tumor site, cytotoxic reactive oxygen species (ROS)
are generated via a so-called type I (electron transfer)
mechanism or via a type II (energy transfer) pathway.14−19
These two competing pathways may also occur simultaneously,
and the ratio between these processes depends on many
parameters such as the type of PS used, the concentrations of
substrate and dioxygen, and the localization of the photo-
sensitizer.14,16 In the design of new PSs, metal complexes
derived from heterocyclic ligands, especially polypyridyl
ligands, have attracted a great amount of attention for their
tunable photophysical properties and their visible light
absorption, which greatly improve the light penetration of
biological tissues compared to that of UV-light-sensitive
molecules.13,20−24 Short-wavelength (blue or green) PDT
agents, although traditionally considered to be academic
curiosities due to the low tissue penetration of this type of
visible light, are regaining interest for certain cancers of thin
organs, such as skin and bladder, because the thickness of the
tumors in such cancers matches the penetration depth of blue
light and green light well.25
More particularly, cyclometalated metal complexes, in which
a metal−nitrogen bond is replaced by a metal−phenylene
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bond, have been considered to be a way to improve the
efficiency of metal-based PDT sensitizers. Cyclometalated
complexes are indeed known for the significant red shift of
their absorption maxima compared to that of polypyridyl
analogues, enhanced stability in solution, and improved cellular
uptake.26 The latter is usually claimed to be due to their
decreased charge and increased lipophilicity compared to those
of polypyridyl analogues.20,26 However, little is known of the
cyclometalated metal complexes’ fate in cell media, which is a
complex mixture of many small biological molecules and
proteins.27 These biomolecules might interact with cyclo-
metalated complexes to generate either new molecular species
or supramolecular aggregates, resulting in modified cellular
uptake and biological properties.28,29 Recently, Thomas’s
group reported a series of cyclometalated [IrIIIRuII]3+
luminescent DNA imaging probes that were prevented to
penetrate the nuclei of cancer cells by reaction with the serum
albumin present in cell growing media, while their polypyridyl
analogue [IrIIIRuII]4+ retained nuclear staining properties in
serum-containing media.30 Che’s group also reported a self-
assembled platinum/gold system for controlled drug release
and accumulation in tumors.31 Coincidentally, many cyclo-
metalated complexes in the literature have been shown to
produce fluorescent dots in the cytoplasm and not to reach the
nucleus,31−33 an organelle that selectively sorts out particles of
small sizes.34
Palladium(II) complexes have been proposed as possible
analogues of antitumor platinum complexes for their similar d8
coordination sphere and tetradentate square-planar structure.
Recently, two palladium-based PDT sensitizers, Padoporfin
and its derivative Padeliporfin, have been clinically approved to
treat prostate cancer, which demonstrates the potential of
palladium complexes for PDT.15,35 Encouraged by these
developments, our group recently studied the influence of
the position of the Pd−C bond in cyclometalated palladium
complexes based on tetrapyridyl ligand Hbbpya (N,N-bis(2,2′-
bipyrid-6-yl)amine) with respect to their photodynamic
properties.36 The isomer characterized by a Pd−C bond on
the side of the noncoordinated NH bridge of this ligand shows
better blue-light absorption and a better singlet oxygen
generation ability compared to the isomer where the Pd−C
bond lies further from the NH bridge. However, in these
complexes the deprotonation of the noncoordinated NH
bridge becomes easy upon palladation of the ligand, resulting
in insoluble neutral metal complexes, thus limiting their
application for cancer treatment in vivo. In this work, we
methylated this NH bridge and synthesized three analogous
palladium complexes: cyclometalated isomers [1]OAc
(N^N^C^N coordination) and [2]OAc (N^N^N^C coordi-
nation), and the reference tetrapyridyl complex [3](OAc)2
(N^N^N^N coordination, Scheme 1). All palladium com-
plexes, prepared with acetate counterions, were water-soluble.
With this new series of complexes at hand, it was possible to
address the influences of cyclometalation and isomerism on the
aggregation and fate of these metal complexes in vitro and in
vivo and to study how proteins present in serum influenced
their speciation and uptake.
■ EXPERIMENTAL SECTION
Compound Preparations. The starting materials and precursors
HL1−HL3 were prepared according to literature methods.36 The
preparation details of ligands MeL1, MeL2, and MeL3 and
corresponding metal complexes [PdMeL1]OAc ([1]+), [PdMeL2]-
OAc ([2]+), and [PdMeL3](OAc)2([3]
2+) are given in the
Supporting Information (SI). All solvents and reagents were
purchased from commercial vendors and used without purification.
All synthesis was performed in a dinitrogen atmosphere. The metal
complexes were synthesized and purified without column chromatog-
raphy in high yields. In the subsequent report, the complexes are all in
the CH3COO
− counterion unless otherwise specified.
Partition Coefficient (log Pow) Determination. The partition
coefficients of palladium complexes were determined by the shake-
flask method. In brief, the palladium complexes were dissolved in
octanol-saturated water and ultrasonicated for 1 h to prepare 1 mM
stock solutions. After filtering with a 0.2 μM membrane filter, aliquots
of the stock solutions (0.2 mL) were transferred per duplicate to 15
mL centrifuge tubes and diluted up to 1 mL using octanol-saturated
water. Then, 1 mL of water-saturated octanol was added to one of the
tubes, and the mixtures were shaken in an IKA Vibrax shaker for 24 h
at 2200 pm. The mixture was centrifuged for 20 min at 4300 rpm to
separate the water phase. An aliquot of the water phase (0.4 mL) was
first mixed with 0.8 mL of 65% HNO3 and then diluted with Milli-Q
water (4.8 mL) to make an 8.7% HNO3 solution (6 mL). The
palladium content of these samples was determined by ICP-OES
using a Vista-MPX CCD simultaneous ICP-OES. Partition coefficient
log Pow was calculated using the equation below
= [ ] [ ] = [ ] − [ ] [ ]Plog log( Pd / Pd ) log( Pd Pd )/ Pdow oct aq total aq aq
where [Pd]total is the concentration of palladium in the control sample
(where no water-saturated octanol was added) and [Pd]aq is the
concentration of palladium in the aqueous layer.
Single-Crystal X-ray Crystallography. The CH3COO
−
counterion of [1]+ and [2]+ was changed to the PF6
− ion by adding
excess KPF6 to a water solution of the acetato metal complexes to
obtain a precipitate of [1]PF6 and [2]PF6 that was filtered off and
dried. Single crystals suitable for X-ray structure determination were
obtained for [1]PF6 and [2]PF6 via slow evaporation of a solution of
the metal complex (PF6 counterion) in a MeCN/EtOAc mixture
(2:1). Single crystals of [3]BF4 were obtained via vapor diffusion from
diethyl ether to a MeCN/EtOAc solution of [3](OAc)2 containing
HBF4. All reflection intensities were measured at 110(2) K using a
SuperNova diffractometer (equipped with an Atlas detector) with Mo
Kα radiation (λ = 0.71073 Å) for [1]PF6 and [3](BF4)2 and with Cu
Kα radiation (λ = 1.54178 Å) for [2]PF6 via the CrysAlisPro program
(Version CrysAlisPro 1.171.39.29c, Rigaku OD, 2017). The same
program was used to refine the cell dimensions and to reduce the
data. The structure was solved with the SHELXS-2018/3 program
(Sheldrick, 2018) and was refined on F2 with SHELXL-2018/3
(Sheldrick, 2018). Numerical absorption correction based on
Gaussian integration over a multifaceted crystal model was performed
using CrysAlisPro. The temperature of the data collection was
controlled using the Cryojet system (manufactured by Oxford
Instruments). The H atoms were placed at calculated positions
(unless otherwise specified) using the AFIX 43 or AFIX 137
instructions with isotropic displacement parameters having a value of
1.2Ueq or 1.5Ueq for the attached C atoms. For [2]PF6, the H atoms
attached to N1 and N21 were found from difference Fourier maps,
and their coordinates were refined pseudofreely. The H1···H21
distance was set to be found within an acceptable range (>1.9 Å)
using the DFIX instructions.
Scheme 1. Structures of the Metal Complexes
Journal of the American Chemical Society pubs.acs.org/JACS Article
https://dx.doi.org/10.1021/jacs.0c01369
J. Am. Chem. Soc. 2020, 142, 10383−10399
10384
Photophysical Property Measurements. Absorption spectra of
complexes were recorded on a Cary 50 spectrometer from Varian.
The emission spectra and relative phosphorescence quantum yields of
metal complexes in aerated water were obtained via a FLS900
spectrometer from Edinburgh Instruments Ltd. The phosphorescence
lifetime of complexes in aerated water was measured by LifeSpec-II
from Edinburgh Instruments, with an excitation source of a 375 nm
pulsed diode laser (pulse width <90 ps). The relative singlet oxygen
quantum yield (φΔ) of complexes was measured in deuterated
methanol on a special custom-built setup described previously, with
[Ru(bpy)3]Cl2 (Tris(bipyridine)ruthenium(II) chloride) as the
standard (φΔ = 0.73).
37,38 For the measurement of φΔ in Opti-
MEM medium, see the Supporting Information.
Calculated Values and TDDFT-Calculated Spectra of Metal
Complexes. The structures of complexes [1]+, [2]+, and [3]2+ were
minimized by DFT at the PBE0/TZP level for all atoms including Pd,
as implemented in the ADF2017 suite from SCM, using COSMO to
simulate solvent effects (in water), scalar relativistic effects for Pd, no
frozen core, and starting from the X-ray structures of [1]PF6 and
[2]PF6. The 20 first singlet-to-singlet electronic transitions were also
calculated with TDDFT using ADF2017 and at the same level of
theory using the Davidson method. Dimer {[1]+}2 was minimized at
the same level of theory as monomer [1]+.
Aggregation of Metal Complexes in Different Aqueous
Solutions According to Dynamic Light Scattering (DLS). DLS
was chosen to determine the numbers and sizes of particles in
complex solutions (5 and 50 μM) in H2O, PBS, and Opti-MEM
medium with and without FCS (fetal calf serum) proteins via the
ZEN1600 Zetasizer Nano instrument (Malvern Instruments Limited)
operating with a 633 nm laser.
Transmission Electron Microscopy (TEM) Measurement of
Metal Complexes in Different Solutions. The TEM experiments
were carried out with a TEM JEOL 1010:100 kV transmission
electron microscope using a Formvar/carbon-coated copper grid from
Polysciences Inc. For the preparation of samples, each drop (15 μL)
of complex solution was deposited on parafilm. The grids were placed
on top of the drops for 2 min, and then the excess liquid on the grid
was removed with filter paper and dried for 2 h for TEM
measurement. The TEM measurements were carried out under
vacuum conditions.
Cryogenic Transmission Electron Microscopy (Cryo-TEM)
Measurements. Sample (6 μL, [complex] = 50 μM) was applied to
a freshly glow-discharged carbon 200 mesh Cu grid (lacey carbon
film, Electron Microscopy Sciences, Aurion, Wageningen, The
Netherlands). Grids were blotted for 3 s at 99% humidity in a
Vitrobot plunge-freezer (FEI VitrobotTM Mark III, Thermo Fisher
Scientific). Cryo-TEM images were collected on a Talos L120C
(NeCEN, Leiden University) operating at 120 kV. Images were
recorded manually at a nominal magnification of 4300× or 13 500×
yielding a pixel size at the specimen of 29.9 or 5.9 Å, respectively.
Cell Culture. Cells were thawed and at least passaged twice before
starting cytotoxicity experiments. For normoxia experiments, cells
were cultured in DMEM completed medium (Dulbecco’s Modified
Eagle Medium with phenol red, supplemented with 8.0% v/v fetal calf
serum (FCS), 0.2% v/v penicillin/streptomycin (P/S), and 1% v/v
glutamine) under humidified normoxic conditions (37 °C atmos-
phere, 21% O2 and 7.0% CO2) in 75 cm
2
flasks. They were
subcultured upon reaching 70−80% confluence, approximately once
per week. Cells were passaged for never more than 8 weeks. For the
cytotoxicity assay, Opti-MEM complete medium without phenol red
was used, supplemented with 2.5% v/v fetal calf serum (FCS), 0.2%
v/v penicillin/streptomycin (P/S), and 1% v/v glutamine). For
hypoxia cytotoxicity experiments, cells were cultured in DMEM
complete medium for at least 2 weeks under humidified hypoxic
conditions (37 °C atmosphere, 1.0% O2, and 7.0% CO2) before
starting hypoxic cytotoxicity tests.
Photocytotoxicity Assay. The working solutions of the three
complexes were typically prepared from 1.0 mM stock solutions of the
complex in distilled water. The cell irradiation system consists of a
Ditabis thermostat (980923001) fitted with two flat-bottomed
microplate thermoblocks (800010600) and a 96-LED array fitted to
a standard 96-well plate. The 455 nm LED (FNL-U501B22WCSL),
fans (40 mm, 24 V DC, 9714839), and power supply (EA-PS 2042-
06B) were ordered from Farnell. A full description of the cell
irradiation setup is given in Hopkins et al.39 The photocytotoxicity
assay was carried out via the sulforhodamine B (SRB) assay reports.40
Briefly, a certain number of cells (5000 cells for A549, 8000 cells for
A431) were seeded in 96-well plates at t = 0 in a volume of 100 μL of
Opti-MEM complete medium without phenol red and incubated for
24 h under normoxic (21% O2) or hypoxic (1% O2) conditions. The
cells were treated with a freshly prepared solution of the complexes in
Opti-MEM at different concentrations in triplicate on the same plates
at t = 24 h. The concentrations of complexes were tuned depending
on their cytotoxicity. At t = 48 h, the irradiation plates were irradiated
with blue light under normoxic (455 nm, 5 min, 5.66 mW cm−2, 1.7 J
cm−2) or hypoxic (455 nm, 8 min, 3.54 mW cm−2, 1.7 J cm−2)
conditions, while the dark plates were kept nonirradiated. After light
irradiation, all plates were incubated in the dark for another 48 h
under normoxic or hypoxic conditions, respectively. Then, the cells in
each well were fixed with trichloroacetic acid (TCA, 10% w/v), gently
washed with distilled water, and stained with 100 μL of SRB (0.6% w/
v in 1% v/v acetic acid/H2O solution). The SRB dye was then
solubilized with Tris base (10 mM, 200 μL), and the absorbance in
each well was read at 510 nm using a M1000 Tecan Reader. Three
independent biological replicates were completed for each cell line.
The obtained data were analyzed with Graphpad Prism 5 using the
dose−response two-parameter Hill slope equation (eq 1) to obtain
the half-maximal effective concentrations EC50 (defined as the
concentration of drug that gives a half-maximum effect).
= + − ×Y 100/(1 10 )X((log EC ) Hill slope)10 50 (1)
Cellular Uptake Inhibition. A549 cells (5 × 105 cells) were
seeded in six-well plates, incubated for 24 h under normoxic
conditions, and then treated with NaN3 (active uptake inhibitor,
15.4 mM) or dynasore (dynamin-dependent endocytosis inhibitor, 80
μM) for 1 h; after that, the cells were incubated with one of the three
palladium complexes (5 μM) for 3 h. To remove the surface-bound
drug, the cells were first washed thrice using with ice-cold PBS. Then
the cells were counted via a cell-counting board three times, collected
by centrifugation, and 7 mL of cell lysis buffer (RIPA Lysis and
Extraction Buffer, Thermo Scientific) was added. Ultrasonication was
then realized for 3 h at 37 °C to afford clear samples. If precipitation
was still observed, HNO3 (65 % 1 mL) was added to the samples, and
the sample was heated for 6 h at 100 °C with a parafilm on the top to
prevent solution evaporation. Once back at room temperature, each
sample was then diluted with Milli-Q water to reach a volume of 10
mL; this solution was finally injected into a PerkinElmer NexION
2000 ICP-MS to measure the Pd concentration.
Cellular Uptake and Localization. A549 cells (5 × 105 cells)
were seeded in T-75 flasks, incubated for 24 h in Optimum medium at
37 °C under 5% CO2, and then treated with complexes [1]OAc−[3]-
(OAc)2 (1 μM, 15 mL), and the control groups were treated with
equal volumes of medium. After 24 h of incubation under normoxic
conditions, the cells were washed with ice-cold PBS (20 mL) three
times and then collected in a 15 mL centrifuge tube and diluted to 10
mL with ice-cold PBS. Then the cells were counted via a cell-counting
board three times. Then the Pd contents of the cells were determined
by ICP-MS using the same protocol as described above. For cellular
fractionation, a FractionPREP Cell Fractionation Kit was used
according to the supplier’s instructions to prepare the cytosol,
membranes, nucleus, and cytoskeleton fractions using the other half of
the cell lysis solution. The samples in each fraction were used directly
to detect the Pd content by ICP-MS.
Measurement of Intracellular ROS. The generation of ROS
(reactive oxygen species) in A549 cells was measured using ROS
fluorescence indicator 2,7-dichlorodihydrofluorescein diacetate
(DCFH-DA).19 After acetate cleavage by cellular esterases, DCFH-
DA can be oxidized by ROS to 2′,7′-dichlorofluorescein (DCF),
which exhibits strong green fluorescence that can be detected by
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fluorescent microscopy or flow cytometry. A549 cells (1 × 105) were
seeded into 24-well plates and incubated for 6 h in the dark. The cells
were then treated with 5 μM complexes and labeled as dark or blue
light groups. After 24 h of incubation under normoxia, the media were
refreshed and the cells were treated with DCFH-DA (20 μM) for 30
min at 37 °C. After that, the blue light group was irradiated with 455
nm blue light for 5 min (5.66 mW cm−2, 1.7 J cm−2). Then the cells
were washed with PBS twice, harvested, and centrifuged (3 min ×
2000 rpm) to remove supernatant. The cells were resuspended in 200
μL of PBS per well in a 96-well plate. Untreated cells were maintained
as negative controls, whereas a 400 μM H2O2 solution in Opti-MEM
complete was administered to another set of three wells for 1 h as a
positive control for ROS. The levels of intracellular ROS were
examined using the Guava easyCyte HT flow cytometer. Gates were
applied over forward scattering, side scattering, and forward scattering
area measurements when possible to remove cellular debris and select
only for singlet whole cells for further statistical analysis. The GRN-B
parameter (488 nm excitation, 525/30 nm emission) was used for
fluorescence measurements given its close proximity to the known
excitation/emission wavelengths of DCF (498/522 nm, respectively).
All flow cytometry data were processed using FlowJ10.
Apoptosis Determination. The apoptosis of A549 cells induced
by metal complexes was determined with an Annexin V-FITC/
propidium iodide double-staining assay. The assay was performed
according to the manufacturer’s (Bio-Connect BV) protocol. A549
cells were seeded in six-well plates with 2 mL of Opti-MEM complete
medium (2 × 105 cells/well), incubated for 6 h, and then treated with
the three complexes (15 μM) and cisplatin (15 μM) for 24 h in the
dark and under normoxia. Then one plate treated with complexes was
irradiated for 5 min with 455 nm blue light (5.66 mW cm−2, 1.7 J
cm−2), named as the blue light group. The cells were all further
incubated in the dark for 24 h under normoxia, after which cells were
harvested and then resuspended in 200 μL of 1× annexin binding
buffer (purchased from Sanbio B.V.). The resulting cell suspension
(200 μL) was stained with 5 μL of Annexin-V-FITC and 5 μL of
propidium iodide (purchased from Sanbio B.V) for 15 min at room
temperature in the dark and then detected by flow cytometry
immediately. Parameters GRN-B (488 nm excitation, 525/30 nm
emission) and RED-B (488 nm excitation, 661/15 nm emission) were
used for fluorescence measurements given their close proximity to the
known excitation/emission wavelengths of Annexin V-FITC (494/
518 nm) and propidium iodide (535/617 nm). All flow cytometry
data were processed using FlowJo10.
Three-Dimensional Tumor Spheroid Viability Assay. The
cytotoxicity of complex [1]+ in 3D tumor spheroids was determined
with a CellTiter-Glo 3D cell viability assay.41 A549 cells (500 cells/
200 μL per well) were added to a 96-well round-bottomed Corning
spheroid plate microplate and centrifuged for 6 min at 800g to
produce tiny tumor spheroid cores that were incubated under
normoxia for 120 h to generate 3D tumor spheroids (658 ± 52 μm
diameter) At t = 120 h, 100 μL of medium was carefully pipetted out
from each well while avoiding the pipetting of spheroids; then the
spheroids were immediately treated with 100 μL of an Opti-MEM
complete medium solution of complex [1]+ with a range of
concentrations to reach final concentrations in the wells of 0, 2, 10,
20, 40, 100, and 200 μM. Each concentration was repeated in
technical triplicate on the same plate. The spheroids were incubated
further under normoxia. At t = 144 h, one plate was irradiated with
blue light under air (455 nm, 10 min, 3.48 mW cm−2, 2.1 J cm−2), and
the other was left in the dark in a normoxic incubator. The spheroids
were further incubated under normoxia in the dark. At t = 192 h, a
CellTiter Glo 3D solution (100 μL/well) was added to each well to
stain the 3D tumor spheroids. After 30 min of shaking on an IKA
Vibrax shaker at 500 rpm at room temperature, the luminescence in
each well was measured with a Tecan microplate reader. Half-maximal
effective concentrations (EC50) for 3D tumor spheroid growth
inhibition were calculated by fitting the CellTiter Glo3D dose−
response curves using the same nonlinear regression function as in 2D
(eq 1) as implemented in Graphpad Prism 5.
In Vivo Experiments. Tumor-bearing female BALB/c mice were
originally purchased from Vital River Laboratory Animal Center
(Beijing, China). The mice were kept under specific pathogen-free
conditions with free access to standard food and water. This study was
conducted in accordance with the Guide for the Care and Use of
Laboratory Animals published by the U.S. National Institutes of
Health (eighth edition, 2011). All protocols for animal studies
conformed to the Guide for the Care and Use of Laboratory Animals.
All animal experiments were performed in accordance with guidelines
approved by the ethics committee of Peking University. The tumor
model was established by injecting 1 × 107 of 4T1 breast cells
suspended in 100 μL of PBS into the right flank region of each mouse
to obtain a mouse 4T1 breast tumor implant. The tumor volume (V)
can be calculated with equation V = L/2 × W2 after measuring the
tumor length (L) and width (W) using a vernier caliper.42 The mice
were randomly divided into six groups (control, 450 nm light, [1]+
dark, [2]+ dark, [1]+ + 450 nm light, and [2]+ + 450 nm light groups)
when the tumor volume reached about 40 mm3. The mice were
treated through paracancerous injection with saline (control and 450
nm light groups), [1]+ (40 μM, 100 μL, 0.01 mg/kg), and [2]+ (40
μM, 100 μL, 0.01 mg/kg). One hour after injection, 450 nm
irradiation (50 mW cm−2, 20 min, 60 J cm−2) was then carried out in
450 nm irradiation, [1]+ + 450 nm, and [2]+ + 450 nm groups. The
tumor volume and body weight of each mouse were measured and
recorded, and the average tumor volume and body weight were
calculated (N = 3) over a period of 10 days.
■ RESULTS
Synthesis and Characterization. The three titled
palladium complexes, [1]+−[3]2+ were synthesized as acetate
salts by reacting methylated ligands MeL1, MeL2, and MeL3
with palladium acetate (Scheme S1). All complexes were
obtained in high yield without chromatography and were
characterized by NMR (Figures S7−S12), HRMS, elemental
analysis, and single-crystal X-ray diffraction (ESI). The acetate
counteranions provided good water solubility and similar log
Pow values of −1.88, −1.92, and −1.71, respectively. These
values suggested similar cellular uptake efficacy if the three
molecules would remain as monomers in aqueous solutions. It
Table 1. Selected Bond Distances (Angstroms) and Angles (Degrees) in the Crystal Structures of [1]PF6, [2]PF6, and
[3](BF4)2
[1]PF6 [2]PF6 [3](BF4)2
Pd−N1 2.1086(17) Pd−N1 2.0544(18) Pd−N1 2.048(2)
Pd−N2 1.9860(19) Pd−N2 2.0435(18) Pd−N2 1.979(2)
Pd−C17 1.9786(18) Pd−N4 2.0096(18) Pd−N4 1.983(2)
Pd−N4 2.0912(18) Pd−C22 2.019(2) Pd−N5 2.034(2)
Pd−Pd 4.223, 3.353 Pd−Pd 4.316, 3.275 Pd−Pd 6.814, 8.373
N1−Pd−N2 81.00(7) N1−Pd−N2 80.88(7) N1−Pd−N2 81.75(9)
N2−Pd−C17 92.19(8) N2−Pd−N4 92.04(7) N2−Pd−N4 92.97(9)
C17−Pd−N4 80.94(7) N4−Pd−C22 82.33(8) N4−Pd−N5 81.67(9)
N4−Pd−N1 105.77(7) C22−Pd−N1 104.52(8) N5−Pd−N1 103.64(9)
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is noteworthy that the 1H NMR spectra of cyclometalated
complexes [1]+ and [2]+ showed significant differences at low
and high concentrations, while [3]2+ did not show this effect
(Figure S13). Thus, NMR suggested that cyclometalation may
promote aggregation in this type of complex.43,44
Single crystals of [1]PF6, [2]PF6, and [3](BF4)2, were
obtained by the slow evaporation of a MeCN/EtOAc solution
or by vapor diffusion from diethyl ether to a MeCN/EtOAc
solution in presence of KPF6 or HBF4 (SI). The crystals were
analyzed by single-crystal X-ray diffraction. Crystallographic
data and a selection of interatomic distances and angles are
shown in Table S1 and Table 1, respectively. All three
complexes crystallized in the triclinic P1̅ space group. As
shown in Figure 1a, [1]PF6 and [2]PF6 were coordination
isomers, with three nitrogen atom and one carbon atom
coordinated to the palladium(II) cation and bond lengths in
the range of 1.9786(18)−2.1086(17) Å. Four nitrogen atoms
are coordinated to palladium in reference complex [3](BF4)2.
The coordination sphere of these three complexes was slightly
distorted, as shown by the small dihedral angle in complexes
[1]PF6 (N1−N2−C17−N4 = 3.96°), [2]PF6 (N1−N2−N4−
C22 = 2.91°), and [3](BF4)2 (N1−N2−N4−N5 = 5.42°). τ4,
a structural parameter used to distinguish square-planar from
tetrahedral coordination complexes (τ4 = 360° − (α + β)/
(141°), where α and β are the two greatest valence angles of
the coordination sphere),45 was 0.112 for [1]PF6, 0.109 for
[2]PF6, and 0.097 for [3](BF4)2, suggesting that these
complexes are essentially square planar. The two cyclo-
metalated, monocationic palladium complexes also showed
clear π−π* stacking and short Pd−Pd distances (3.275−4.316
Å), suggesting the occurrence of Pd···Pd metallophilic
interaction.46 In contrast, reference complex [3](BF4)2 had
higher Pd···Pd distances (6.814−8.373 Å) that were almost
twice as long, indicating the absence of Pd···Pd interaction in
this bicationic compound (Figure 1b). Interestingly, these
metal−metal interactions stimulate cyclometalated complexes
[1]PF6−[2]PF6 to self-assemble.47−49 Overall, X-ray crystal-
lography was consistent with NMR results and suggested that
Pd···Pd metallophilic interaction may occur both in solution
and in the solid state.
Figure 1. Molecular view of the cationic complexes (a) and their stacking (b) in the crystal structures of [1]PF6, [2]PF6, and [3](BF4)2.
Displacement ellipsoids are shown at the 50% probability level. Pd···Pd distances are indicated in angstroms. Counterions and disorder have been
omitted for clarity.
Figure 2. (a) Absorption (solid line, left axis) and normalized emission spectra (dashed line, right axis) of [1]OAc−[3](OAc)2 in water (50 μM,
350 nm excitation). (b) Singlet oxygen emission for solutions of [1]+−[3]2+ in CD3OD (450 nm excitation, A450 = 0.1).
Journal of the American Chemical Society pubs.acs.org/JACS Article
https://dx.doi.org/10.1021/jacs.0c01369
J. Am. Chem. Soc. 2020, 142, 10383−10399
10387
Photophysical Characterization and Frontier Orbi-
tals. The photophysical properties of [1]OAc−[3](OAc)2 in
water are shown in Figure 2 and Table 2. Importantly (see
below) under such conditions none of the molecules aggregate.
Complexes [2]+ and [3]2+ showed intense absorbance
essentially in the ultraviolet range (300−400 nm), but a
bathochromically shifted absorption band was observed for
[1]+, characterized by an absorption maximum at 428 nm. As a
result, in pure water the molar absorptivity values at 455 nm
for the three complexes were 1500, 37, and 56 M−1 cm−1,
respectively, indicating that while [2]+ or [3]2+ are bad blue
light PDT sensitizers, [1]+ may be good at it. The difference in
blue light absorption can be explained by the different
HOMO−LUMO orbital energy gaps of the three compounds.
According to DFT at the PBE0/TZP/COSMO level (Figure
S14, Table S2), the HOMO and LUMO orbitals of all three
complexes have π symmetry and have a very low (5.55% for
[1]+) to zero (for [2]+ and [3]2+) contribution of the
palladium centers. The HOMO is centered on the non-
coordinated amine bridge NMe of the ligand, and in the two
cyclometalated complexes, its energy is strongly affected by
how close the electron-rich Pd−C− bond is to NMe (EHOMO =
Table 2. Photophysical Data for Complex [1]OAc−[3](OAc)2
lifetime (ns)a,d
complex λabs, nm (ε × 10
3 M−1 cm−1)a λem (nm)
a φp τ1 τ2 φΔ
e
[1]OAc 428 (2.12), 455 (1.50) 593 0.0029b 0.159 ± 0.003 0.78f, 0.73g
[2]OAc 344 (6.10), 455 (0.037) 509 0.00038b 0.211 ± 0.008 0.052f
[3](OAc)2 364 (7.45), 455 (0.056) 430 0.0038
c 0.309 ± 0.003 (87%) 4.17 ± 0.08 (13%) 0.009f
aMeasurements were carried out in Milli-Q water. bPhosphorescence quantum yield measurements of [1]+−[2]+ were carried out at a 390 nm
excitation wavelength in aerated water using [Ru(bpy)3]Cl2 (φp = 0.028) as the standard.
50 cPhosphorescence quantum yield measurements of
[3]2+ were carried out at a 350 nm excitation wavelength in aerated ethanol using 9,10-diphenylanthracene (φp = 0.885) as the standard.
50
dExcitation wavelength 375 nm. eExcitation wavelength 450 nm, air atmosphere. The absorption of each complex at 450 nm was adjusted to 0.1 to
avoid the generation of excimer. fIn CD3OD by spectroscopic detection at 1270 nm; [Ru(bpy)3]Cl2 was used as the standard (φΔ = 0.73).
38 gIn
Opti-MEM complete using 9,10-anthracenediyl-bis(methylene)dimalonic acid as the 1O2 probe; [Ru(bpy)3]Cl2 was used as the standard (φΔ =
0.14; see the SI for details).
Figure 3. (a) Dynamic light scattering derived count rate of [1]+−[3]2+ at 5 or 50 μM in pure water, PBS, and Opti-MEM medium with or without
FCS (2.5% v/v). Size distribution of the DLS analysis of solutions of [1]+−[3]2+ (50 μM) in Opti-MEM medium with (b) or without (c) FCS. The
X axis is the hydrodynamic diameter (in nm); the Y axis is intensity (%).
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−6.24 eV for [1]+, −6.58 eV for [2]+). On the other hand, the
LUMO is based on the bipyridine fragment of the ligand, and
its energy is hence essentially independent of the position of
the electron-rich Pd−C− bond (ELUMO = −2.41 eV for [1]+,
−2.46 eV for [2]+). For [3]2+, the HOMO was slightly
stabilized compared to that of [2]+ due to the more electron-
poor nature of the tetrapyridyl ligand compared to its
cyclometalated version (Table S2). The resulting HOMO−
LUMO energy gaps of the three complexes follow the series
[1]+(3.83 eV) ≪ [2]+(4.11 eV) < [3]2+(4.13 eV), which
explains the better absorption of [1]+ in the blue region of the
spectrum. These results were confirmed by time-dependent
density functional theory calculations (TDDFT, see Figure
S15). Compounds [1]+−[3]2+ showed their lowest-energy
transitions at 412, 368, and 369 nm, respectively, and these
lowest-energy transitions corresponded to 97.5, 95.2, and
98.1%, respectively, for the HOMO → LUMO transition. The
excited states of these complexes, which must be of triplet
multiplicity considering the heavy nature of the palladium
atom and the efficient formation of 1O2 (see below), hence
have intraligand charge transfer character (3ILCT). The
phosphorescence emission from these states was similarly
weak and very short in aerated Milli-Q solutions (Figure 2a),
with quantum yields (φp) lower than 0.5% and lifetimes of
between 150 and 310 ps (Table 2, Figure S16). However, their
quantum yields for 1O2 generation (φΔ), which were measured
under 450 nm excitation by direct detection of the 1274 nm
infrared emission of 1O2 in CD3OD, were very different
(Figure 2b, Table 2). [1]+ showed the best 1O2 quantum yield
(0.78, compared to 0.73 for the reference [Ru(bpy)3]Cl2),
37
followed by [2]+ (0.052) and finally [3]2+ (0.009). Overall,
[1]+ shows excellent properties for blue-light PDT, including
good light absorption around 450 nm and excellent 1O2
generation efficiency in air, while [2]+ is only slightly better
than [3]2+, which has negligible photodynamic properties.
Aggregation of the Metal Complexes in Cell Culture
Medium. In this family of palladium complexes, cyclo-
metalation of bicationic complex [3]2+ lowers its charge from
+2 to +1, which influences the supramolecular interaction of
the metal complexes with itself and with other charged
biomolecules. The NMR and crystallographic studies discussed
above stimulated us to compare the behavior of complexes
[1]+−[3]2+ at 5 or 50 μM in a series of biomimetic solvents:
H2O, PBS, Opti-MEM cell medium with 2.5% fetal calf serum
(FCS; this mixture is hereafter called Opti-MEM complete),
and Opti-MEM without FCS. The formation of nano-
aggregation in the biomimetic solvents was studied with
dynamic light scattering (DLS). All three palladium complexes
dissolved well in water and PBS solution, as shown by the low
DLS-derived count rate (in kcps), indicating that no
aggregation occurred under these conditions (Figure 3a,
Table S5). In contrast, in the present of Opti-MEM cell
medium with or without FCS, cyclopalladated complexes
[1]+−[2]+ definitely aggregated into particles, with a 35-fold (5
μM) or 102-fold (50 μM) increase in the derived count rate
values. However, the derived count rate for [3]2+ in all
biomimetic solvents remained at a low level. The difference
behavior of complexes [1]+−[3]2+ in Opti-MEM demonstrates
the significant influence of cyclometalation and complex charge
on the aggregation properties of these palladium complexes. In
addition, the size of the aggregates made in the [1]+−[2]+ in
medium utterly depended on the presence of serum proteins
(Figure 3b, Figure S17). In the medium with FCS, the particle
distribution maxima were at 458 and 396 nm at 50 μM
concentration (Figure 3b). In the absence of FCS, micro-
particles (hydrodynamic diameter >1000 nm) were formed,
resulting in precipitation (Figure 3c). Upon increasing the
palladium complex concentration from 5 to 50 μM, the
nanoparticles at around 10−100 nm, which belong to the FCS
proteins, almost disappeared and were replaced by micro-
meter-sized particles (Figure S17). For bicationic complex
[3]2+, no significant changes occurred in the DLS analysis
when the concentration was varied from 5 to 50 μM in all
solutions, showing the absence of aggregation for this
compound (Figure 3, Figure S17). Meanwhile, the acidic
nature of cancer cells51 stimulated us to observe the
aggregation behavior of [1]OAc in cell medium at different
pH values (3.30−7.64). As shown in Figure S18, [1]+ still
formed nanoaggregates (100−1000 nm) while the size
distribution maximum slightly increased with pH, suggesting
possible aggregation of this compound in the more acidic
environment of cancer cells or in the lysosome.
Another view of the chemical stability and aggregation
behavior of these complexes in different media was provided
by following in time the absorbance spectra of solutions of
[1]+−[3]2+ in H2O, PBS, and Opti-MEM cell medium with or
without FCS (Figure S19). All complexes were stable in water
and PBS solutions for 24 h, confirming that the tetradentate
nature of the ligand prevents the coordination of water or
chloride ligands to the metal center. In addition, the complexes
were stable in the presence of GSH and ascorbic acid (Figure
S19), showing that palladium(II) was not reduced under such
conditions. In cell medium with FCS, [1]+−[2]+ showed
significant increases in the baseline absorbance over 24 h,
which can be attributed to increased scattering by the
nanoparticles forming in solutions.52 In contrast, in the
medium without FCS the absorbance decreased quickly during
the first 15 min and remained essentially constant in a second
step, which can be assigned to precipitation. For [3]2+, the
absorbance did not vary significantly in the medium without
FCS, confirming the higher solubility of the bicationic
complex. However, in FCS-containing medium a dramatic
change was observed, characterized by an isosbestic point at
358 nm, indicating a chemical reaction between [3]2+ and one
of the components of FCS. These results matched the
observations made by DLS (i.e., [1]+−[2]+ precipitated in
medium without FCS but generated ∼400 nm hydrodynamic
diameter nanoparticles when FCS was added to the cell
medium). This result suggests that the proteins present in FCS
play a dramatic role in the aggregation state of cyclopalladated
compounds [1]+−[2]+, while for tetrapyridyl complex [3]2+
this role is much less pronounced. We can hence expect a
different mechanism of cell uptake for monocationic complexes
[1]+−[2]+ compared with dicationic compound [3]2+ because
many cell uptake pathways, including endocytosis, depend on
the size of drugs.53,54 In addition, the aggregation of [1]+−[2]+
in an FCS-containing medium suggests that upon injection
into the bloodstream of a mammal these types of cyclo-
metalated compounds may generate protein-caped nano-
particles, which may influence the tumor uptake and biological
half-time of cyclometalated compounds compared to non-
aggregated small molecules such as [3]2+.
Supramolecular Polymerization of Cyclometalated
Complexes. If the data above demonstrated that nano-
aggregates were stabilized in FCS-containing medium, it was
not clear yet as to whether the palladium complex or proteins
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abundant in serum, such as albumin, were responsible for
aggregate formation. As [1]OAc−[3](OAc)2 do not form
aggregates in pure water and form them too quickly in Opti-
MEM complete, we changed their counteranion to hexa-
fluorophosphate by reprecipitation with KPF6 to make them
less hydrophilic, which allowed for observing the kinetics of the
formation of the nanorods. Supramolecular live polymerization
of [1]PF6 and [2]PF6 was observed in H2O/MeCN solution
(100 μM, 9:1, v/v) via UV−vis absorption spectroscopy.48 As
shown in Figure 4a,b,d, for [1]PF6 and [2]PF6 the baseline of
the absorbance spectrum increased quickly (within 6 to 7
min), suggesting increasing light scattering; it then stabilized
until the end of the experiment (t = 30 min). By contrast, the
absorbance of [3](PF6)2 showed only negligible variations
(Figure 4c,d). At the end of these UV−vis experiments, each
solution was deposited on a TEM grid to observe the
morphology of the nanoaggregates by TEM. Complexes
[1]PF6 and [2]PF6 showed beautiful nanorod morphologies,
while [3](PF6)2 showed random aggregates reminiscent of a
precipitate. These data clearly show that cyclometalated
complexes [1]+−[2]+ themselves are able to self-assemble
into nanorods most probably due to the Pd···Pd interaction
observed in the solid state.
Cryo-TEM Measurements in Opti-MEM Medium.
Compounds [1]OAc−[3](OAc)2 dissolve well in water with
a low derived count rate according to DLS (Figure 3a). TEM
gives a higher-contrast picture: while samples of [1]OAc−
[2]OAc prepared from a Milli-Q water solution (50 μM)
showed rectangular nanorods with an average length of around
139 and 203 nm, respectively, samples of [3](OAc)2 at the
same concentration showed random shapes characteristic of a
precipitate (Figure S20). In both cases, the observed
particulates were artifacts due to evaporation of the solvent
prior to TEM imaging. Cryo-TEM, on the contrary, allows for
observing nanostructures directly as they are in solution (i.e.,
in their native state). Cryo-TEM images of a 50 μM solution of
[1]OAc-[3](OAc)2 under different conditions were hence
recorded. As shown in Figure 5 and Figure S21, the two
cyclometalated compounds [1]OAc−[2]OAc in Opti-MEM
did generate nanorods characterized by a width of ∼20 nm. In
the presence of FCS, these nanorods were nicely dispersed on
the grid or were forming aggregates of about 500 nm, while in
the absence of FCS they aggregated in much larger
Figure 4. Time evolution of the absorption spectra of the H2O/MeCN solution (100 μM, 9:1, v/v) of complexes [1]PF6 (a), [2]PF6 (b), and
[3](PF6)2 (c) at 298 K for 30 min. (d) Time evolution of the absorption at 428 nm (black stars, [1]PF6), 332 nm (red dots, [2]PF6), 360 nm
(green triangles, [3](PF6)2) of these solutions. The absorption spectra were measured every 30 s. (e) TEM images of [1]PF6 (a), [2]PF6 (b), and
[3](PF6)2 (c) after aggregation in the H2O/MeCN solution (100 μM, 9:1, v/v) for 30 min (scale bar 5 μm, inset 1 μm).
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superaggregates of micrometer size. Compound [3](OAc)2, on
the contrary, did not show such nanorods. Interestingly, when
[1]OAc (50 μM) was dispersed in pure FCS solution, bent
nanofibers were observed, indicating that the proteins
contained in FCS also played a role in the generation of
nanostructures. Overall, all cryo-TEM images were fully
consistent with the DLS results. From these data, it appears
that FCS stabilized nanorods in the cell medium for
cyclometalated compounds [1]OAc−[2]OAc while in the
absence of FCS the nanorods aggregate with each other into
larger clusters that end up precipitating out of solution.
Influence of the Charge on the Supramolecular
Interaction. In order to understand why [1]+ and [2]+ self-
assemble and not [3]2+, we first minimized by DFT at the
PBE0/TZP/COSMO level in water a supramolecular dimer of
[1]+ and [2]+ (Figure S22, Table S6). Minimization converged
with a local minimum characterized by Pd···Pd distances of
3.18 and 3.20 Å, respectively, which qualitatively fits the
experimental distance observed in the crystal structure (3.35
and 3.27 Å, respectively; see Figure 1b). This minimum
demonstrates that for two isolated molecules of cyclo-
metalated, monocationic complex [1]+ or [2]+, electrostatic
repulsion is low enough to be compensated for by the
metallophilic Pd···Pd interaction, coupled to π−π stacking of
the flat polyaromatic ligands. By contrast, a similar
minimization run from a dimer of [3]2+, assembled by hand
at a short (3.18 Å) Pd···Pd distance, saw the Pd···Pd distance
increase steadily to >6.5 Å during energy minimization,
without converging (data not shown). This result demon-
strated that for [3]2+ the charge and hence the intermolecular
electrostatic repulsion are too high to be compensated for by
the metallophilic interaction and the π−π stacking that may
occur at short Pd···Pd distances. Thus, the supramolecular
assembly of [1]+ and [2]+ seems to be modulated by the
environment of the complex in solution (solvent, counter-
anions, and the presence of proteins), but it is an inherent
property of these cyclometalated metal complexes. It originates
from the strong and attractive combination between the
metallophilic interaction and π−π stacking between the ligands
at short Pd···Pd distances, combined with low electrostatic
repulsion. For [3]2+, the latter is too strong to lead to
supramolecular assembly.
Photophysical and Photochemical Properties of
[1]OAc in Opti-MEM Complete Medium. As in a cell
cytotoxicity assay, the cyclometalated complexes will be added
Figure 5. Cryo-TEM images of complexes [1]OAc and [3](OAc)2
(50 μM) in Opti-MEM medium with or without FCS or in pure FCS
solution.
Figure 6. Singlet oxygen generation of aggregates of [1]OAc in Opti-MEM complete medium. (a) The absorbance change of ABMDMA (100
μM) in Opti-MEM complete in the presence of [1]OAc (50 μM) in the dark (top) or upon blue light irradiation (bottom). (b) Evolution of the
absorbance at 378 nm vs irradiation time of ABMDMA (100 μM) in Opti-MEM complete medium in the absence or presence of [1]OAc (50 μM)
or [Ru(bpy)3]Cl2 (50 μM) in the dark or under blue light irradiation. Irradiation conditions: 298 K, 450 nm, 5.23 mW cm
−2, and 1 min.
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in Opti-MEM complete medium and not in water or methanol,
they will form aggregates rather than monomers. It is hence
important to determine whether aggregation modifies the
photophysical and photochemical properties of [1]OAc
compared to the monomer. The absorbance (Figure S23a)
of [1]OAc in medium, for example, showed on top of a
broader and more intense absorption band between 350 and
500 nm a baseline increasing with decreasing wavelengths,
which is typical for light scattering by nanoaggregates. Blue
light absorption was improved for the aggregates compared to
that for the monomer. The weak emission peak at 593 nm for
[1]OAc in water (Figure S23b) was quenched in Opti-MEM
complete medium and replaced by a new stronger peak with a
maximum at 469 nm. This new peak was located in a similar
region compared to the emission peak of Opti-MEM complete
medium itself, but it was more intense. The exact nature of the
emitters responsible for this new band remains unknown; in
particular, it is unclear whether this peak might be attributed to
supramolecular associations between [1]OAc and endogenous
fluorophores in the medium. All in all, the emission properties
of the supramolecular aggregates of [1]OAc were still too low
to be observed in vitro by emission microscopy.
In terms of the 1O2 generation quantum yield (φΔ), direct
spectroscopic detection of the 1270 nm emission of 1O2, which
was used for determining φΔ of the monomer in CD3OD,
could not be used in a nondeuterated aqueous cell-growing
medium, where the intensity of this NIR emission band was
too low. Hence, to determine the value of φΔ of aggregates of
[1]OAc in Opti-MEM medium, a specific water-soluble 1O2
probe was used (i.e., 9,10-anthracenediyl-bis(methylene)-
dimalonic acid (ABMDMA)). In the dark, this dye absorbs
light at around 378 nm, but in the presence of photogenerated
1O2, it forms an endoperoxide that leads to a loss of
conjugation and thus a decrease in absorbance at 378 nm.55
When [1]OAc (50 μM) was mixed with ABMDMA (100 μM)
in Opti-MEM complete, the absorbance remained stable in the
dark; however, upon 450 nm light irradiation the absorbance
of ABMDMA dramatically decreased (Figure 6), showing the
good 1O2 production of the aggregates of [1]OAc. A high
quantum yield of 0.73 was obtained by a quantitative
comparison of the slope obtained with [1]OAc with the
slope obtained with a reference sample of [Ru(bpy)3]Cl2 (50
μM, φΔ,ref = 0.14, see Figure S24 and details in the SI).
56
Overall, [1]OAc retains excellent 1O2 generation properties in
Table 3. Half-Maximal Effective Concentrations (EC50 in μM) of [1]
+−[3]2+, Cisplatin, 5-ALA, and Rose Bengal for A549 and
A431 Cancer Cells in the Dark and under Blue Light Irradiation under Normoxic (21% O2) and Hypoxic (1% O2)
Conditionsa,b
EC50 (μM)
normoxic condition hypoxic condition
complex A549 ±CI A431 ±CI A549 ±CI A431 ±CI
[1]+ dark 2.2 +0.4 45 +13 6 +3 100 +70
−0.4 −9 −2 −28
light 0.33 +0.15 4.8 +0.9 1.3 +0.3 15 +2
−0.11 −0.8 −0.3 −2
PI 6.7 9.4 4.6 6.7
[2]+ dark 2.7 +0.7 12 +4 4 +1 29 +38
−0.6 −3 −1 −13
light 2.5 +0.7 7 +2 3 0.9 22 +18
−0.6 −1 −0.8 −8
PI 1.1 1.4 1.3 1.3
[3]2+ dark 5 +2 7 +2 23 +8 21 +2
−2 −2 −5 −1
light 4.4 +0.9 6 +1 15 +4 21 +3
−0.9 −1 −3 −3
PI 1.1 1.2 1.5 1.0
cisplatin dark 3.1 +0.6 2.5 +0.4 24 +11 13 +4
−0.5 −0.4 −5 −3
light 3.9 +0.8 2.9 +0.5 20 +8 8 +2
−0.7 −0.4 −4 −2
PI 0.79 0.86 1.2 1.6
5-ALA dark 390 +620 11000 +2200 13300 +3400 16 800 +2800
−270 −1900 −2700 −2400
light 170 +250 1200 +1900 14400 +3500 19 200 +4500
−110 −850 −2900 −3700
PI 2.3 9.2 0.9 0.9
rose bengal dark 63 +13 57 +28 76 +18 70 +22
−11 −18 −16 −21
light 21 +6 8 +1 81 +24 74 +20
−4 −1 −19 −19
PI 3.0 7.1 0.9 0.9
aThe 95% confidence interval (CI in μM) and photoindexes (PI = EC50,dark/EC50,light) are also indicated.
bIrradiation condition: normoxic 455 nm,
5 min, 5.66 mW cm−2, and 1.7 J cm−2; hypoxic 455 nm, 8 min, 3.54 mW cm−2, and 1.7 J cm−2. The data is the mean of three independent
biological experiments.
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the aggregated state and its blue light absorption properties are
improved (i.e., its blue light PDT properties are improved in
cell growing medium).
Phototoxicity Assay under Normoxic and Hypoxic
Conditions. Considering the good photodynamic properties
of [1]+ under blue light irradiation and its FCS-stabilized
nanoaggregation behavior, the anticancer activities of [1]+−
[3]2+ were studied first in vitro, both in the dark and following
a low dose of blue light (1.7 J cm−2). A dose−response curve
was obtained in two human cancer cell lines A549 (lung
cancer) and A431 (skin cancer) grown in 2D under normoxia
(21% O2) and using FCS-containing medium. The sulforhod-
amine B (SRB) assay was used as an end-point assay to
quantify cell viability in treated vs untreated wells, and cisplatin
was used as the positive control. The half-maximal effective
concentrations (EC50), defined as the compound concen-
tration necessary to divide cell growth by a factor of 2,
compared to untreated wells, and the photoindexes (PI),
defined as EC50,dark/EC50,light, are reported in Table 3. In A549,
all three complexes showed significant anticancer abilities in
the dark (EC50 < 10 μM), comparable to that of cisplatin,
while in A431 [3]2+ was much more toxic than [1]+−[2]+.
This result suggests that the cyclopalladated complexes, unlike
[3]2+, might have a form of cell toxicity in the dark that is cell-
specific. Upon blue light irradiation, complex [1]+ showed a
6.7- and 9.4-fold increase in cytotoxicity toward A549 and
A431 cancer cells, respectively, to reach 330 nM cytotoxicity
for A549 cells, which is 9.4 more toxic than cisplatin (3.1 μM
in dark). These results are in line with the excellent singlet
oxygen generation properties of this compound under blue
light irradiation, and they were comparable, at such low doses
of light (<2 J.cm−2), to the photoindex obtained with the
clinically approved 5-ALA control (PI = 9.8 in normoxic A431
cells, see Table 3). Meanwhile, compounds [2]+−[3]2+ did not
show any significant photocytotoxicity, which is consistent
with their very low blue light absorption.
The excellent singlet oxygen generation properties of
[1]OAc in both monomeric and aggregated forms and its
clear blue light activation in normoxic cells suggested that this
compound may work via a type II PDT mechanism (i.e., via
energy transfer from the 3ILCT states of the complex to 3O2).
When the cytotoxicity experiment was repeated in the same
cancer cells grown under hypoxia (1% O2, Figures S25−S27),
the phototoxicity of [1]+ indeed showed a 3-fold decrease.
However, it was not fully quenched because the photoindexes
of 4.6 and 6.7 in A549 and A431, respectively, were smaller
compared to 6.7 and 9.4 only under normoxia, respectively, but
far from unity. By contrast, two well-known PDT type II
photosensitizers, 5-ALA and rose bengal, when used as positive
controls, showed a good PDT effect (PI < 10) under normoxic
conditions but no phototoxicity at all under hypoxic
conditions, as expected for PDT type II photosensitizers.
These results suggest that PDT type I may also occur with
[1]+, as observed with other metal-based sensitizers.14 Finally,
the higher EC50 obtained in the dark for [1]
+−[3]2+ under
hypoxic conditions can be rationalized by the different
microenvironments and gene expression usually found in
hypoxic cancer cells, which are known to overexpress resistance
mechanisms compared to normoxic cells.
Cellular Uptake, Subcellular Fractionation, and
Uptake Inhibition Studies with A549 Cells. Usually,
nanoaggregates are taken up by endocytosis and end up either
in the endosome or lysosome.57 In order to check this
hypothesis, A549 cells were first treated for 1 h with sodium
azide (15.4 mM) or dynasore (80 μM), which inhibited active
uptake and dynamin-dependent endocytosis, respectively.58
Then, the cells were incubated with the three palladium
complexes (5 μM) for a short time (i.e., 3 h). The Pd contents
of the cells were finally determined by ICP-MS. As shown in
Figure 7a, in the control group without any inhibitors the drug
uptake of cyclometalated compounds [1]+−[2]+ was 3 times
higher than that of tetrapyridyl analogue [3]2+. In addition,
samples pretreated with NaN3 or dynasore showed significant
inhibition efficiency for the uptake of [1]+−[2]+, while no
inhibition was observed for [3]2+. These results clearly
demonstrated that [1]+−[2]+ were taken up in the cell via
active, dynamin-dependent endocytosis, while [3]2+ went into
the cells by energy-independent uptake, possibly passive
diffusion. This assay confirmed that [1]+−[2]+ entered the
cells as nanoaggregates and that cyclometalation dramatically
changed the mechanism of cell uptake.
In a second experiment aimed at determining the intra-
cellular localization, at longer incubation times for these
nonemissive palladium complexes, A549 cells were treated
with complexes [1]OAc−[3](OAc)2 (1 μM) for 24 h and then
trypsinized and fractionated into four fractions: cytosol,
membranes, nuclei, and cytoskeleton. The membrane fractions
include not only the cell membrane but also the membranes in
the mitochondria, endosomes, and lysosomes. In principle,
nanoaggregates of [1]+−[2]+ were expected to end up in the
membrane fraction. The results (Figure 7b, Table S7) did not
fit such expectations. [1]+−[2]+ were found neither in the
membrane nor in the nuclear fractions but almost exclusively
(94.3 and 89.1%, respectively) in the cytoskeleton fraction. In
Figure 7. (a) Pd contents (expressed in μg Pd/million cells) of A549 cells after treatment with NaN3 or dynasore for 1 h and compounds [1]
+−
[3]2+ (5 μM) for 3 h. (b) Distribution (expressed in ng Pd/million cells) of palladium compounds [1]+−[3]2+ in the cytosol (black), membranes
(red), nucleus (blue), and cytoskeleton (green) of A549 cells after treatment at 1 μM for 24 h.
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contrast, [3]2+ was distributed among the cytoskeleton
(61.1%), the membrane fraction (15.5%), and the cytosol
(23.3%). In addition, as at shorter times the total amount of
palladium found in the cells was more than 10 times higher for
cyclometalated complexes [1]+−[2]+ (19 and 14 ng Pd/
million cells, respectively) than for [3]2+ (1.7 ng Pd/million
cells). Overall, these combined ICP-MS results confirmed
previous reports that cyclometalated compounds are more
efficiently taken up than their polypyridyl analogue. However,
they also shed new light on the reason for such enhanced
uptake: considering their similar log Pow values but very
different aggregation behavior in the FCS-containing cell
medium, it is the nanoaggregation of cyclometalated
compounds [1]+−[2]+, stabilized by FCS, that leads to
enhanced cellular uptake rather than passive uptake by
diffusion through the cell membrane. In addition, the
supramolecular nature of the interactions leading to aggregate
formation seems weak enough to allow for a redistribution of
the palladium complex after endocytosis, as palladium ends up
in the cytoskeleton fraction rather than in the endosome or
lysosome. According to this study, the mode of action of [1]+−
[2]+ is very unlikely to be related to nuclear DNA damage,
suggesting that these compounds may overcome chemo-
therapy resistance originating from DNA damage repair.
Intracellular ROS Determination and Apoptosis. The
generation of ROS in cancer cells usually induced cell death via
apoptosis.59 2,7-Dichlorodihydrofluorescein diacetate (DCFH-
DA) is an excellent sensor for intracellular ROS, which
generates green-emissive metabolite 2′,7′-dichlorofluorescein
(DCF). ROS levels were hence measured in A549 cells using
flow cytometry after treatment with [1]+−[3]2+ (5 μM),
followed or not by blue light irradiation (455 nm, 5 min, 5.66
mW cm−2, 1.7 J cm−2; Figure 8a). In the dark, cyclometalated
complexes [1]+−[2]+ showed significant ROS levels, even
higher than that for the positive control (400 μM H2O2).
Upon 455 nm irradiation, the ROS levels in all groups
increased, especially for complex [1]+, with a 3.5-fold
enhancement and the highest ROS level of all samples. This
experiment confirmed the photodynamic character of light-
induced cell killing with [1]+. The ROS level found for [2]+
under blue light irradiation was close to the sum of the ROS
levels found in cells treated with only blue light and that of
cells treated with [2]+ and left in the dark, indicating the weak
light-induced ROS generation ability of complex [2]+.
Unexpectedly, [3]2+ inhibited ROS generation, compared
with cells treated with [3]2+ but kept in the dark or cells
irradiated with blue light in the absence of any compound. The
cytotoxicity difference between cyclometalated complexes
[1]+−[2]+ and [3]2+ is the ability of the former to generate
ROS in the dark and the ability of [1]+ to absorb blue light to
increase ROS generation.
The cell death mode triggered by such ROS formation in
A549 cells was determined by flow cytometry using the
Annexin V-FITC/propidium iodide double-staining assay
(Figure S28). After 24 h of incubation with each complex,
the A549 cells were irradiated with blue light or left in the dark
and incubated for another 24 h and then harvested and treated
with both dyes for FACS analysis. The percentage of live cells
(Annexin −, PI −), early apoptotic (Annexin + , PI −), later
apoptotic (Annexin +, PI +), and necrotic (Annexin −, PI +)
cells are shown in Figure 8b. Clearly, in the dark [1]+−[3]2+
provoke cell death via apoptosis. Under blue light irradiation,
the percentage of apoptotic cells induced by complex [1]+
increased by 21% (from 71 to 92%), while the other two
complexes increased by only 4.3% ([2]+) and 7.1% ([3]2+).
Overall, in A549 cells [1]+ kills cells via apoptosis in the dark
by generating ROS near the cytoskeleton; this action is
dramatically enhanced by low doses of blue light irradiation.
Photocytotoxicty of [1]OAc in Three-Dimensional
Tumor Spheroids. In 2D cell monolayers, the physical
access of the drug to the cancer cells is not an issue, and light
optimally and equally bathes all cells, which represents a poor
model of in vivo tumor treatment with PDT. By contrast, 3D
multicellular tumor spheroid models provide a more accurate
biological evaluation of the physical penetration of PDT drugs,
nanoparticle-based drug delivery systems, and light.60 The
cytotoxicity of [1]+ in FCS-containing medium was hence
tested in 3D tumor spheroids using a CellTiter-Glo 3D cell
viability end-point assay to quantify the ATP concentration.41
As shown in Figure 9, it was possible to fully eradicate the
tumor spheroids in the dark, suggesting that the nano-
aggregates of [1]+ and FCS either well penetrated the spheroid
to kill simultaneously all cell layers including the center or
destroyed the outer layers of the spheroids first to move
Figure 8. (a) Mean fluorescence intensity of cells treated first with [1]OAc−[3](OAc)2 (5 μM, 24 h) and then with DCFDA (20 μM, 30 min) and
analyzed by flow cytometry. (b) Flow cytometry quantification of alive (Annexin −, PI −), early apoptotic (Annexin +, PI −), later apoptotic
(Annexin +, PI +), and necrotic (Annexin −, PI +) A549 cells after treatment with [1]+−[3]2+ (15 μM) or cisplatin (15 μM) in the dark or after
irradiation for 5 min with blue light (455 nm, 5.66 mW cm−2, 1.7 J cm−2).
Journal of the American Chemical Society pubs.acs.org/JACS Article
https://dx.doi.org/10.1021/jacs.0c01369
J. Am. Chem. Soc. 2020, 142, 10383−10399
10394
toward the center and kill the cells there. Upon blue light
activation (455 nm, 10 min, 3.48 mW cm−2, 2.1 J cm−2), the
EC50 value of 3D tumor spheroids decreased by 6.2-fold, from
13 to 2.1 μM, and here as well full eradication of ATP
production could be achieved. Such a photoindex is
surprisingly similar to the one measured in normoxic 2D cell
monolayers (6.7), which again suggests that sensitizer
penetration is not an issue here. These results not only
confirm the excellent potential of [1]+ as a blue light PDT
agent but also highlight its ability to penetrate, as a
nanoaggregate, to the core of tumor spheroids and to kill all
cancer cells by a combination of a chemical (dark toxicity) and
photochemical (blue-light activation) effect.
In Vivo Experiments. The penetration of blue light well
matches the depth of skin cancers in the human body.
Considering the excellent dark cytotoxicity of [1]OAc in vitro
and its good photodynamic properties in hypoxic cancer cells
and 3D tumor spheroids, the in vivo antitumor property of
compound [1]OAc was evaluated, in the dark or upon blue
light irradiation (450 nm), in 4T1 breast tumor xenografts in
Balb/c female mice. This model is a commonly used
subcutaneous tumor model in mice, which is better suited
for blue light PDT in vivo than orthotopic xenografts models
because of the short irradiation wavelength used. In general,
intravenous tail injection is the main injection method for in
vivo antitumor experiments because it best mimics the mode of
administration of PDT sensitizers in clinical trials. However, in
this work the higher dark cytotoxicity of the palladium
complexes, compared to clinically approved PDT sensitizers,
led us to consider paracancerous injection and a short drug-to-
light interval of 1 h as a more efficient method for maximizing
the drug concentration near the tumor and hence the PDT
effect, while minimizing toxicity to the mice. Compound
[2]OAc was also tested as a control complex that also forms
nanoparticles in the presence of proteins, but does not absorb
blue light at that wavelength. The mice (N = 3) were divided
into six groups when the tumor volume reached around 40
mm3: dark vehicle control, blue light-irradiated vehicle control,
and injection of [1]OAc or [2]OAc (40 μM, 100 μL) either
with or without blue light irradiation in a 60 J cm−2 light dose.
The mice were treated twice, at days 0 and 2. One hour after
compound injection, the mice were irradiated with blue light
for 20 min. The tumor volume of each mouse (Figure 10a) and
the body weight (Figure S29) were measured and recorded
over a period of 10 days following treatment. At day 10, the
mice were sacrificed, and tumors were isolated to compare the
volume scale of tumor spheres. All mice showed similar body
weight at the end of the treatment (around 20 g), meaning that
the mice were healthy and the complexes were not very toxic
to the mice itself. At day 10, the tumor of dark vehicle control
and blue-light-irradiated vehicle control groups showed similar
(and highest) volumes, followed by the mice group treated
with [2]+ (dark) > [2]+ (450 nm) > [1]+ (dark) > [1]+ (450
nm). In the dark, the tumor volumes of mice were gradually
growing with the treatment of complex [1]+ and [2]+ from day
0 to day 8 and then significantly increased on day 10. When
treated with [1]+ and irradiated with blue light on days 0 and
2, no obvious growth of the tumor occurred over 10 days
(Figure 10a), demonstrating the excellent photodynamic
therapy properties of [1]+ under these conditions.
As a side note, when the intravenous tail injection of a PDT
sensitizer is chosen, longer drug-to-light intervals are typically
used (4−24 h) in order to wait for the PDT sensitizer to
accumulate in the tumor, in particular, for sensitizer nano-
formulations relying on the enhanced permeability and
retention (EPR) effect to enter the tumor.61 By contrast,
paracancerous injection is a quicker and more direct method of
concentrating the sensitizer (here the Pd nanoaggregates) near
the tumor site. Also, it is better than intratumoral injection
because paracancerous injection still holds the possibility of
blood circulation of the drug to occur. On the other hand, a
longer drug-to-light interval could lead to further transport of
the drug to the rest of the body and unwanted toxicity to
occur. Thus, a rather short drug-to-light time of 1 h was
chosen. The final results suggest that 1 h is indeed a reasonable
time setting and that under such conditions [1]+ penetrates
well enough into the tumor to serve as a PDT sensitizer.
■ DISCUSSION
Traditionally, a vast majority of the PDT literature argues that
because light penetration is better with red light than with blue
Figure 9. Dose−response curves for A549 3D tumor spheroids
incubated with complex [1]+ irradiated for 10 min with blue light (in
blue) or kept in the dark (in black). EC50,dark = 13 μM (95%
confidence intervals +7.7 μM, −6.0 μM), EC50,light = 2.1 μM (95%
confidence intervals +0.7 μM, − 0.7 μM), PI = 6.2.
Figure 10. (a) Relative 4T1 breast tumor volumes of Balb/c mice and
(b) visual tumor sizes at day 10 of Balb/c mice treated with vehicle
control, [1]+, or [2]+ at day 0 and left in the dark or irradiated with
blue light. Mice were treated on days 0 and 2 and irradiated with blue
light (450 nm, 50 mW cm2, 20 min, 60 J cm−2) 1 h after injection.
Statistical significance was set to p < 0.01 (**) and 0.001 (***).
Journal of the American Chemical Society pubs.acs.org/JACS Article
https://dx.doi.org/10.1021/jacs.0c01369
J. Am. Chem. Soc. 2020, 142, 10383−10399
10395
light, blue light PDT is not relevant in vivo. Recently, however,
research compared blue light vs red light for the 5-
aminolevulinic acid (ALA) photodynamic therapy of basal
cell carcinoma patients.62,63 5-ALA is transformed selectively
by tumors into protoporphyrin IX, which can be excited either
in the Soret band using blue light or in the Q band using red
light. In this study, blue light showed statistically noninferior
efficacy compared to red light, and a lower light fluence rate
could be used with blue light due to the better light absorption
of the Soret band, which generated less pain for the patients.62
These results suggested that blue light PDT should be studied
and optimized further to evaluate its potential as an effective
nonscarring anticancer treatment option in, for example, skin,
eye, or bladder cancer. In cancers of superficial tissues indeed,
short-wavelength (blue or green) PDT agents are interesting
because short-wavelength light potentially reduces the damage
to deeper healthy tissues. For skin cancer, for example, skin
contains two layers: the cuticular layer (∼0.08−0.27 mm
thickness) and the derma (∼2.1−5.9 mm thickness).64 As in
skin tissue the penetration depth for blue, red, and NIR light is
1−2, 4−5, and >5 mm, respectively,65 blue light may reduce
photodynamic damage to the derma. It is known that the
cuticular tissue can recover soon after damage, but for the
derma, tissue recovery is sometimes difficult. Thus, in the
treatment of skin diseases, it is beneficial to reduce damage to
the derma. Similar strategies are being developed in bladder
cancer patients, where the green light PDT sensitizer
(TLD1433) is currently in a clinical phase II trial13 to alleviate
the phototoxicity issues experienced with red light PDT using
photofrin in the end of the 1990s.66 Recently, Lilge’s group
reported a method to formulate TLD1433 with transferrin,
which improved molar extinction coefficients in the visible
domain of the spectrum, ROS production by the photo-
sensitizer, cellular uptake, and the in vivo PDT efficacy.67
These results provide an inspiring example on how to further
improve the photoactivity of cyclometalated PDT compounds
such as [1]+.
In the present study, [1]+ stands out for two reasons. First, it
is an excellent singlet oxygen generator under blue light
irradiation, while [2]+ and [3]2+ have negligible absorption and
singlet oxygen generation properties at such wavelengths. The
bathochromically shifted absorbance of [1]+ is a consequence
of the lower HOMO−LUMO gap in this compound due to (i)
the presence and (ii) the position of the Pd−C bond with
respect to the noncoordinated amine bridge.36 The photo-
dynamic properties of [1]+ were observed in both normoxic
and hypoxic 2D cell monolayers, suggesting that [1]+ can serve
for both PDT type II (normoxia) and type I (hypoxia).
Second, the self-aggregation properties of [1]+ and [2]+ cause
them to efficiently penetrate cancer cells via endocytosis where
it is distributed to the cytoskeleton, while [3]2+ is taken up in
smaller amounts and is codistributed in the membranes and
cytosol. These self-assembly properties are a direct conse-
quence of the lower charge of the cyclometalated complexes, of
their extended, flat aromatic ligand, of the presence of a
palladium(II) atom in the center of the complexes, which
generates Pd···Pd metallophilic interaction,49,68,69 and of the
stabilization of the self-assembled nanorods in a biological
medium by serum proteins. One should also note that
although aggregation is often detrimental to the photodynamic
properties of porphyrin sensitizers, for example, with cyclo-
metalated palladium compounds such as [1]+, self-assembly
leads to nanostructures without quenching the blue-light
photoreactivity. Of course, aggregation of the Pd complex as
nanorods in the cell medium suggests that aggregation may
also occur in the blood and that sensitizer uptake by the tumor
may partially rely on the enhanced permeability and retention
(EPR) effect via the trans-endothelial pathways.70 However, at
that stage these hypotheses remain speculations. Altogether,
the excellent uptake, localization, and photodynamic properties
of [1]+ make it an interesting blue-light-activated tumor killer
not only in the 3D spheroid model but also in 4T1 breast
tumor xenografts in mice.
■ CONCLUSIONS
For metal-based anticancer drugs and photosensitizers,
achieving cytotoxicity requires efficient cellular uptake. The
most common method for increasing cellular uptake, which
consists of increasing the lipophilicity of the compounds,
allows for a better crossing of the lipophilic phospholipid
bilayer of cells. Cyclometalation is one way to enhance the
lipophilicity of metal complexes, and it almost systematically
significantly improves cellular uptake. On the other hand, such
a strategy is usually detrimental to the selectivity of the uptake
because healthy cells also have a membrane. Our work offers a
new perspective on the effects of cyclometalation on cell
uptake beyond a simple increase in molecular lipophilicity.
First, the octanol−water partition coefficient (log P) is always
measured in the absence of serum protein, so similar log P
values do not necessarily allow for predicting the solubility and
aggregation properties of a drug candidate in cell growth
medium or in blood. Second, when the balance between
hydrophobicity and self-assembly properties is just right,
cyclometalated complexes such as palladium complexes [1]+
and [2]+ can generate nanoaggregates. Our results unambig-
uously demonstrate that the colloidal stability of these
aggregates critically depends on the presence of the protein
component (FCS) of the cell-growth medium and that in the
presence of serum, cellular uptake in vitro is greatly enhanced
compared to that of nonaggregated compounds such as [3]2+.
Endocytosis probably plays a critical role here; however, it
should be noted that the compound was finally detected in the
cytoskeleton rather than in the endosome or lysosome, which
suggests that the supramolecular nature of the interaction
responsible for the aggregation (i.e., Pd···Pd metallophilic
interaction) may be reversible in the cell and allow for the
compound to escape the endocytic pathway. Protein-
controlled self-assembly in aqueous solution via Pd···Pd
metallophilic interaction has not been documented before. It
suggests that (pro)drug self-assembly in serum may offer
straightforward strategies for improving drug uptake without a
sophisticated drug delivery system and that such strategies may
work not only in vitro but also in vivo.
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